Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC

NCT03654729 is registered in ClinicalTrials.gov with Egetis Therapeutics as lead sponsor.

NCT NCT03654729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03654729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC
Lead sponsor
Egetis Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
November 7, 2018
Completion date
August 31, 2020
Enrollment
291 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy, colorectal cancer